S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
OTCMKTS:MEDXF

Medexus Pharmaceuticals (MEDXF) Stock Price, News & Analysis

$1.22
-0.02 (-1.61%)
(As of 03/28/2024 ET)
Today's Range
$1.22
$1.23
50-Day Range
$1.11
$2.00
52-Week Range
$0.84
$2.56
Volume
8,031 shs
Average Volume
18,840 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.50
MEDXF stock logo

About Medexus Pharmaceuticals Stock (OTCMKTS:MEDXF)

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Treosulfan, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; Tricovel tablets with Biogenina to reduce hair shedding due to Telogen Eflluvium; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.

MEDXF Stock Price History

MEDXF Stock News Headlines

Medexus Pharmaceuticals Inc.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Medexus Announces Fiscal Q3 2024 Results
MEDXF Medexus Pharmaceuticals Inc.
Medexus Pharmaceuticals reports Q2 results
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Medexus and medac Agree to Amend US Treosulfan Agreement
Medexus Pharmaceuticals Inc (MDP) Receives a Buy from Stifel Nicolaus
See More Headlines
Receive MEDXF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
OTCMKTS:MEDXF
CIK
N/A
Fax
N/A
Employees
98
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.50
High Stock Price Target
$17.50
Low Stock Price Target
$17.50
Potential Upside/Downside
+1,335.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Kenneth d'Entremont
    CEO & Director
  • Mr. Marcel Konrad (Age 48)
    Chief Financial Officer
    Comp: $585.05k
  • Mr. Ian C. Wildgoose Brown
    General Counsel & Corporate Secretary
  • Ms. Tina Byers CFA
    Executive of Investor Relations
  • Mr. Bill Poncy
    Senior Vice President of Commercial Operations - United States
  • Mr. Brian Peters
    Vice President of Sales & Marketing - United States

MEDXF Stock Analysis - Frequently Asked Questions

Should I buy or sell Medexus Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medexus Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MEDXF shares.
View MEDXF analyst ratings
or view top-rated stocks.

What is Medexus Pharmaceuticals' stock price target for 2024?

1 Wall Street analysts have issued 12 month target prices for Medexus Pharmaceuticals' stock. Their MEDXF share price targets range from $17.50 to $17.50. On average, they anticipate the company's share price to reach $17.50 in the next year. This suggests a possible upside of 1,335.6% from the stock's current price.
View analysts price targets for MEDXF
or view top-rated stocks among Wall Street analysts.

How have MEDXF shares performed in 2024?

Medexus Pharmaceuticals' stock was trading at $1.89 at the start of the year. Since then, MEDXF stock has decreased by 35.5% and is now trading at $1.2190.
View the best growth stocks for 2024 here
.

Are investors shorting Medexus Pharmaceuticals?

Medexus Pharmaceuticals saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 69,300 shares, an increase of 56.8% from the February 29th total of 44,200 shares. Based on an average daily trading volume, of 24,800 shares, the days-to-cover ratio is presently 2.8 days.
View Medexus Pharmaceuticals' Short Interest
.

How do I buy shares of Medexus Pharmaceuticals?

Shares of MEDXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:MEDXF) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners